Search hospitals > Maine > Portland
Maine Medical Center
Claim this profilePortland, Maine 04102
Global Leader in Cancer
Global Leader in Coronary Artery Disease
Conducts research for Adenocarcinoma
Conducts research for Ovarian Cancer
Conducts research for Cystic Fibrosis
319 reported clinical trials
21 medical researchers
Summary
Maine Medical Center is a medical facility located in Portland, Maine. This center is recognized for care of Cancer, Coronary Artery Disease, Adenocarcinoma, Ovarian Cancer, Cystic Fibrosis and other specialties. Maine Medical Center is involved with conducting 319 clinical trials across 398 conditions. There are 21 research doctors associated with this hospital, such as Eric C. Larsen, Matthew D. Cheney, Leslie Bradford, MD, and Christine Lu-Emerson.Area of expertise
1Cancer
Global LeaderStage I
Stage IV
Stage II
2Coronary Artery Disease
Global LeaderTop PIs
Eric C. LarsenMaine Children's Cancer Program7 years of reported clinical research
Studies Lymphoma
Studies Leukemia
24 reported clinical trials
67 drugs studied
Matthew D. CheneyMaine Medical Center- Scarborough Campus2 years of reported clinical research
Studies Cancer
Studies Breast Cancer
20 reported clinical trials
58 drugs studied
Leslie Bradford, MDMaine Medical Center- Scarborough Campus3 years of reported clinical research
Expert in Ovarian Cancer
Studies Fallopian Tube Cancer
19 reported clinical trials
49 drugs studied
Christine Lu-EmersonMaine Medical Center- Scarborough Campus2 years of reported clinical research
Studies Glioblastoma
Studies Brain Tumor
6 reported clinical trials
13 drugs studied
Clinical Trials running at Maine Medical Center
Prostate Cancer
Cancer
Small Cell Lung Cancer
Cardiac Arrest
Traumatic Brain Injury
Squamous Cell Carcinoma
Gastric Cancer
Esophageal Adenocarcinoma
Ovarian Tumors
Anal Cancer
Apalutamide + Targeted Radiation
for Prostate Cancer
This phase III trial tests two questions by two separate comparisons of therapies. The first question is whether enhanced therapy (apalutamide in combination with abiraterone + prednisone) added to standard of care (prostate radiation therapy and short term androgen deprivation) is more effective compared to standard of care alone in patients with prostate cancer who experience biochemical recurrence (a rise in the blood level of prostate specific antigen \[PSA\] after surgical removal of the prostate cancer). A second question tests treatment in patients with biochemical recurrence who show prostate cancer spreading outside the pelvis (metastasis) by positron emission tomography (PET) imaging. In these patients, the benefit of adding metastasis-directed radiation to enhanced therapy (apalutamide in combination with abiraterone + prednisone) is tested. Diagnostic procedures, such as PET, may help doctors look for cancer that has spread to the pelvis. Androgens are hormones that may cause the growth of prostate cancer cells. Apalutamide may help fight prostate cancer by blocking the use of androgens by the tumor cells. Metastasis-directed targeted radiation therapy uses high energy rays to kill tumor cells and shrink tumors that have spread. This trial may help doctors determine if using PET results to deliver more tailored treatment (i.e., adding apalutamide, with or without targeted radiation therapy, to standard of care treatment) works better than standard of care treatment alone in patients with biochemical recurrence of prostate cancer.
Recruiting2 awards Phase 3
Standard Therapy + Surgery/Radiation
for Prostate Cancer
This phase III trial studies how well standard systemic therapy with or without definitive treatment (prostate removal surgery or radiation therapy) works in treating participants with prostate cancer that has spread to other places in the body. Addition of prostate removal surgery or radiation therapy to standard systemic therapy for prostate cancer may lower the chance of the cancer growing or spreading.
Recruiting2 awards Phase 330 criteria
Hormone + Radiation Therapy
for Prostate Cancer
This phase III trial compares less intense hormone therapy and radiation therapy to usual hormone therapy and radiation therapy in treating patients with high risk prostate cancer and low gene risk score. This trial also compares more intense hormone therapy and radiation therapy to usual hormone therapy and radiation therapy in patients with high risk prostate cancer and high gene risk score. Apalutamide may help fight prostate cancer by blocking the use of androgen by the tumor cells. Radiation therapy uses high energy rays to kill tumor cells and shrink tumors. Giving a shorter hormone therapy treatment may work the same at controlling prostate cancer compared to the usual 24 month hormone therapy treatment in patients with low gene risk score. Adding apalutamide to the usual treatment may increase the length of time without prostate cancer spreading as compared to the usual treatment in patients with high gene risk score.
Recruiting2 awards Phase 36 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Maine Medical Center?
Maine Medical Center is a medical facility located in Portland, Maine. This center is recognized for care of Cancer, Coronary Artery Disease, Adenocarcinoma, Ovarian Cancer, Cystic Fibrosis and other specialties. Maine Medical Center is involved with conducting 319 clinical trials across 398 conditions. There are 21 research doctors associated with this hospital, such as Eric C. Larsen, Matthew D. Cheney, Leslie Bradford, MD, and Christine Lu-Emerson.
Where is Maine Medical Center located?
Maine Medical Center is located at 22 Bramhall St, Portland, ME 04102.
Who should I call to ask about financial aid or insurance network?
For financial assistance and insurance inquiries at Maine Medical Center, please reach out to Patient Financial Services via MyChart or by calling 1-866-804-2499. Our team is available Monday through Friday, from 8 am to 4:30 pm.
What insurance does Maine Medical Center accept?
Maine Medical Center, a key entity within the MaineHealth system, accepts a broad range of major insurance providers, including but not limited to Aetna, Anthem, Cigna, and Medicare. Patients are encouraged to verify their insurance coverage, including copayments, coinsurances, and deductibles, directly with their insurance carrier or network. Note that coverage for specific services, such as behavioral health, may vary by location and could be managed by subsidiary companies under your health plan.
What awards or recognition has Maine Medical Center received?
Maine Medical Center, acclaimed as Maine's top hospital for 11 consecutive years by U.S. News & World Report, excels in Urology and 13 common procedures and conditions. It stands as an International Learning Collaborative Founding Partner, underscoring its commitment to Fundamental Care globally. The MaineHealth Institute for Research pioneers in biomedical research, advancing patient care through extensive research and clinical trials.